- SM 16
-
- $53.00
-
2026-08-08
- CAS:614749-78-9
- Purity: 99.81%
- Supply Ability: 10g
|
| Product Name: | SM16 | | Synonyms: | 4-[4-(1,3-Benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-2-yl]bicyclo[2.2.2]octane-1-carboxamide;CS-2835;Bicyclo[2.2.2]octane-1-carboxamide, 4-[4-(1,3-benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-2-yl]-;SM16;SM-16,TGF-β Receptor,Inhibitor,inhibit,SM 16,Transforming growth factor beta receptors,SM16;4-[5-(2H-1,3-benzodioxol-5-yl)-4-(6-methylpyridin-2-yl)-1H-imidazol-2-yl]bicyclo[2.2.2]octane-1-carboxamide;SM 16, 10 mM in DMSO | | CAS: | 614749-78-9 | | MF: | C25H26N4O3 | | MW: | 430.5 | | EINECS: | | | Product Categories: | | | Mol File: | 614749-78-9.mol |  |
| Boiling point | 691.3±55.0 °C(Predicted) | | density | 1.354±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:65.0(Max Conc. mg/mL);150.99(Max Conc. mM) | | form | A solid | | pka | 11.23±0.10(Predicted) | | color | White to off-white |
| Uses | SM 16 is a ALK5/ALK4 kinase inhibitor with Kis of 10 and 1.5 nM, respectively. | | Biological Activity | SM 16 is an ALK5/ALK4 kinase inhibitor with Ki values of 10 and 1.5 nM, respectively. | | in vivo | SM 16 penetrates tumor cells in vivo , suppressing tumor phosphorylated Smad2/3 levels for at least 3 h following treatment of tumor-bearing mice with a single ip bolus of 20 mg/kg SM 16. The growth of established AB12 tumors is significantly inhibited by 5 mg/kg/d SM 16 (P<0.001) delivered via sc miniosmotic pumps over 28 days. < /p> | | target | Ki: ALK5 (10 nM), ALK4 (1.5 nM) | | storage | Store at -20°C | | References | [1] Suzuki E, et al. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res. 2007 Mar 1;67(5):2351-9. DOI:10.1158/0008-5472.CAN-06-2389
[2] Fu K, et al. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):665-71. DOI:10.1161/ATVBAHA.107.158030
[3] Engebretsen KV, et al. Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5. J Mol Cell Cardiol. 2014 Nov;76:148-57. DOI:10.1016/j.yjmcc.2014.08.008 |
| | SM16 Preparation Products And Raw materials |
|